Immunization Week, which is celebrated these days, has highlighted the urgent need for a vaccine to tackle Covid-19 and also the fundamental role that immunizations play in protecting populations around the world.

This was recently corroborated by the UN Secretary General, António Guterres, who recognized as the only way out for the world to return to normal an effective vaccine against Covid-19.

Knowing that the development timelines of these medical devices are difficult to predict, scientists around the world are working around the clock to immunize humanity against the coronavirus, especially considering the ravages that the current pandemic is causing: more 2.6 million people worldwide, while the death toll exceeds 184,000.


In this context, the WHO Director-General, Tedros Adhanom, recently reported on several clinical trials of vaccines against SARS-CoV-2, although he was also not very optimistic about the deadlines, calculating that up to 18 months from now it will not be available, as reported by

Despite the accelerated march of some countries for the immediate obtaining of a vaccine, the WHO estimates that this will not be possible until at least a year from now.

One of these clinical trials has started in Germany, after the announcement of its authorization by the German Federal Institute of Vaccines and Biomedicines, Paul-Ehrlich, as reported in a statement echoed by

The first clinical trials of this vaccine, developed by the biotechnology company BioNTech, aim to investigate the general tolerability of the test candidates as well as its ability to induce a specific immune response against the SARS-CoV-2 pathogen. The approval of the study "is the result of a meticulous benefit-risk assessment of the potential vaccine," said the German competent body.

China, the origin of the coronavirus outbreak, was the first to start this race, last March, to obtain immunization, with the idea of ​​avoiding a possible second wave of Covid-19, with new measures, including the trial. clinical with two experimental vaccines in humans, which were started last March as also reported by the same

These experimental vaccines are carried out by a unit of Sinovac Biotech and the Wuhan Biological Products Institute, under the Chinese National Pharmaceutical Group (Sinopharm) and the Sinovac Research and Development Corporation, based in Beijing.

Likewise, last March, another clinical trial of a coronavirus vaccine was authorized in this country, developed by the military-backed Chinese Academy of Military Medical Sciences and the biotechnology firm CanSino Bio (6185.HK).

Also last March, the United States Department of Health and Human Services (NIH) announced the start of a phase 1 clinical trial to evaluate an investigational vaccine at the Kaiser Permanente Washington Health Research Institute ( KPWHRI) in Seattle.

For the trial, which will last about six weeks, 45 healthy adult volunteers aged 18 to 55 have been recruited. Four were the participants who received a dose in mid-March. Each of them will be punctured in the arm on two occasions, 28 days apart between their administration. Likewise, they will be monitored for the next twelve months to monitor its safety and immunogenicity.

The vaccine, known as mRNA-1273, is made up of a segment of mRNA (mRNA-1273) that includes the coronavirus S-spike expression genes.



Another country that has gotten the green light for a clinical trial has been the United Kingdom with the ChAdOx1 nCoV-19 vaccine, whose tests were scheduled precisely for Thursday at the Southampton NHS Trust University Hospital.

Under the name of "ChAdOx1 nCoV-19", it is a type of immunization known as "recombinant viral vector vaccine" and has been developed by the teams at the Jenner Institute at the University of Oxford and by the Oxford Vaccine Group , who started their first jobs last January, and hope to have it ready in late summer.


In the United Kingdom the first clinical trial with a vaccine against Covid-19 has started this Thursday

During the month of May it is expected to be tested on 500 volunteers between 18 and 55 years old. The technology that supports this vaccine has already been used in the development of about 10 different treatments, but, according to those responsible, it needs to be tested in different population groups in different countries to guarantee representative results, since they argue that “infection rates They vary greatly from place to place with prevention measures in place. "

From Switzerland, scientists from the University Hospital of Bern on Tuesday expressed their confidence in obtaining a coronavirus vaccine within a period not exceeding six months, that is, around the month of October. His research, in collaboration with the University of Zurich and the biotechnology industry, is currently in the efficacy and safety testing stage, with the start of clinical trials being calculated for the month of August with 240 volunteers once the approval of the Swissmedic drug control agency.

Meanwhile, Spain is also trying to put its grain of sand in the long-awaited vaccine, as reported earlier this month by the Minister of Science, Pedro Duque, who highlighted the work carried out in this field by the National Center for Biotechnology of the Superior Research Center Sociological (CNB-CSIC). Duque attached such importance to this research that he did not even rule out the possibility that it is Spain that will finally obtain the coronavirus vaccine worldwide.



Enlace original:

The texts on this site have been translated with: Google Translator